Medications to Manage Breakthrough Bleeding on Oral Micronized Progesterone: First-Line and Beyond

At a glance

• Incidence: Irregular bleeding affects approximately 40 to 50% of women in the first year of continuous combined HRT; rates drop to under 10% by month 12 according to the PEPI trial data
• Typical onset: Days 14, 90 after initiating or adjusting OMP dose
• First-line management: Short-course NSAIDs (mefenamic acid 500 mg TID) or tranexamic acid 1 g TID, QID during bleeding days
• Second-line options: Dose or timing adjustment of OMP itself; levonorgestrel IUS consideration in select patients
• When to escalate: Bleeding lasting >10 days per cycle, soaking >1 pad per hour, or any bleeding after 12 months of amenorrhea
• When to discontinue OMP: Confirmed endometrial hyperplasia without atypia unresponsive to optimized progestogen dosing; any atypia or malignancy found on biopsy

Why Breakthrough Bleeding Happens on OMP

Oral micronized progesterone is bioidentical progesterone delivered orally, most commonly as Prometrium 100 mg or 200 mg capsules. When used as the progestogen component of HRT, it protects the endometrium from unopposed estrogen stimulation. However, during the first months of use, or whenever the dose changes, the endometrium cycles through irregular shedding patterns before it stabilizes.

The mechanism is straightforward: estrogen thickens the endometrial lining, while progesterone matures and stabilizes it. When OMP doses are low, inconsistently timed, or first introduced, progesterone receptor saturation is incomplete. Focal areas of the endometrium shed asynchronously, producing breakthrough or irregular bleeding that is not due to pathology but to the endometrium adjusting. This is biologically different from the heavy, prolonged bleeding that signals structural pathology or hyperplasia.

Understanding this distinction matters because it determines which medications are appropriate. The goal of pharmacologic management at this stage is either to reduce the local prostaglandin-driven vascular response causing the bleeding, or to temporarily support endometrial stability while the HRT regimen reaches steady state.

Ruling Out Pathology Before Starting Any Medication

Before reaching for a prescription pad, clinicians and patients should confirm that the bleeding is in fact a side effect of dose adjustment rather than a sign of endometrial disease. The American College of Obstetricians and Gynecologists (ACOG) recommends transvaginal ultrasound as the initial evaluation for any unscheduled bleeding in postmenopausal women on HRT. An endometrial thickness of 4 mm or less on transvaginal ultrasound has a high negative predictive value for endometrial carcinoma, as established in the ACOG Practice Bulletin on abnormal uterine bleeding. If thickness exceeds 4 mm, or if bleeding is recurrent, endometrial biopsy is warranted before initiating any symptomatic treatment.

This is not a formality. A 2016 review in Menopause found that roughly 5% of postmenopausal women investigated for abnormal bleeding on HRT had underlying endometrial pathology. Treating bleeding pharmacologically without this step is a clinical error.

First-Line Medications

NSAIDs: Mefenamic Acid and Naproxen Sodium

NSAIDs are the most widely used and evidence-backed first-line agents for managing abnormal uterine bleeding that is functional in origin. They work by inhibiting cyclooxygenase enzymes, reducing endometrial prostaglandin synthesis, and thereby decreasing uterine vasodilation and blood loss. A Cochrane systematic review of NSAIDs for heavy menstrual bleeding found a mean blood loss reduction of 20 to 49% compared with placebo across multiple study designs.

Mefenamic acid is the most studied agent in this class for uterine bleeding:

• Dose: 500 mg orally three times daily, taken only on bleeding days
• Duration: No longer than 5 consecutive days per episode
• Start: At the onset of bleeding, not prophylactically
• Supplied as: 250 mg and 500 mg tablets (prescription required in the US)

Naproxen sodium is available over the counter (Aleve, 220 mg per tablet) and is a practical alternative for patients who cannot access mefenamic acid quickly:

• OTC dose: 440 mg (two tablets) as a loading dose, then 220 mg every 8 to 12 hours during active bleeding
• Prescription dose: Naproxen 500 mg BID for up to 5 days
• Clinical caveat: Evidence for naproxen in HRT-related bleeding is extrapolated from menorrhagia data, as noted in the NICE heavy menstrual bleeding guideline NG88

Ibuprofen (400 to 600 mg every 6 to 8 hours) is a reasonable OTC substitute when mefenamic acid or naproxen are unavailable, though it is less well studied specifically for endometrial bleeding. The NICE NG88 guideline lists it as an acceptable second-choice NSAID.

Contraindications for all NSAIDs: active peptic ulcer disease, renal impairment (eGFR <30), known cardiovascular disease in patients at high bleeding risk, or concurrent anticoagulant use. Patients on low-dose aspirin should discuss with their prescriber before adding an NSAID.

Tranexamic Acid

Tranexamic acid is an antifibrinolytic agent that reduces bleeding by preventing the breakdown of fibrin clots in the endometrial vasculature. It does not affect ovulation or hormone levels and does not interact with OMP pharmacokinetics. The FDA-approved indication for tranexamic acid (Lysteda) is heavy menstrual bleeding, and the same mechanism applies to HRT-related unscheduled bleeding.

• Prescription dose: 1 to 300 mg (two 650 mg tablets) orally three times daily for up to 5 days during active bleeding
• Generic tranexamic acid: 500 mg tablets, 2 tablets TID is commonly prescribed off-label
• OTC status: Tranexamic acid is not currently available OTC in the United States; it requires a prescription
• Onset: Reduces bleeding volume within the first 24 hours of use, as shown in the key Lysteda trial (Lukes et al., 2010)

A head-to-head comparison published in the British Journal of Obstetrics and Gynaecology found tranexamic acid superior to mefenamic acid for reducing menstrual blood loss in women with objectively confirmed heavy bleeding, with a mean reduction of approximately 54% versus 20%.

Contraindications: active thromboembolic disease, history of DVT or PE (use with caution even in lower-risk patients, as HRT itself carries a background thrombotic risk), and hypersensitivity. The FDA prescribing information for Lysteda notes that the risk of thrombosis is not increased in clinical trial data, but this finding has not been studied specifically in HRT populations with existing clotting risk factors.

Can You Combine NSAIDs and Tranexamic Acid?

Short answer: generally not for routine breakthrough bleeding. The evidence base for combining them is thin, and the practical benefit in mild to moderate unscheduled bleeding is unclear. Each agent addresses a different mechanism, but unless bleeding is very heavy, using one first and escalating is the more defensible approach. If bleeding is heavy enough to require both simultaneously, that is a signal to reassess the HRT regimen itself and perform or repeat endometrial assessment, as recommended in the British Menopause Society guidelines.

Second-Line Options: Adjusting the OMP Regimen

Medication management of the symptom is sometimes less effective than adjusting what is causing it. The British Menopause Society consensus statement on HRT and abnormal uterine bleeding identifies three OMP-specific regimen changes that frequently resolve breakthrough bleeding.

1. Increase OMP dose: Women on 100 mg nightly who experience persistent spotting may respond to 200 mg nightly. Higher progesterone receptor saturation produces more consistent endometrial suppression. This is the most common prescriber-level adjustment.

2. Switch from continuous to sequential OMP: In continuous combined regimens, OMP is taken every day. Some endometria respond better to a sequential regimen (OMP taken for 12 to 14 days per month), which produces a predictable withdrawal bleed and eliminates unpredictable spotting. Data from the PEPI trial support sequential progestogen as producing lower rates of unscheduled bleeding than continuous regimens in the short term.

3. Change the timing of OMP: OMP is often taken at night due to its sedating metabolite (allopregnanolone), but taking it at the same time each day without missing doses reduces day-to-day variation in plasma progesterone levels. Even small gaps in dosing can drop endometrial progesterone support enough to trigger shedding, as described in a pharmacokinetic analysis of oral micronized progesterone published in Fertility and Sterility.

Third-Line and Specialist Options

If first-line medications and regimen adjustments fail after three to six months, the following options are used in specialist practice.

Levonorgestrel-releasing IUS (Mirena): The levonorgestrel IUS (52 mg, releasing approximately 20 mcg/day) is highly effective at preventing endometrial proliferation and eliminating unscheduled bleeding when combined with systemic estrogen. A randomized trial published in Obstetrics and Gynecology found that the levonorgestrel IUS produced amenorrhea in over 70% of HRT users at 12 months. It is licensed in the UK for the progestogen component of HRT. In the US it is used off-label for this purpose. It is not appropriate for patients who prefer oral-only HRT or who have contraindications to IUS insertion.

Oral norethisterone (norethindrone) short course: A 5-day course of norethindrone 5 mg daily can stop an acute bleeding episode by stabilizing the endometrium. This is used as a bridge while the OMP regimen is being adjusted. Clinical guidance from the Faculty of Sexual and Reproductive Healthcare supports short-course norethisterone for this indication. Patients should be aware it may cause mood side effects in the short term.

Referral for hysteroscopy: Persistent unscheduled bleeding despite optimized OMP regimen and absence of pathology on biopsy warrants hysteroscopy to exclude submucosal fibroids, polyps, or focal hyperplasia that biopsy can miss. ACOG guidance on abnormal uterine bleeding identifies hysteroscopy as more sensitive than blind sampling for intracavitary lesions.

What to Avoid: Drug Interactions and Unsafe OTC Choices

Aspirin: Low-dose aspirin does not stop endometrial bleeding and may worsen it by inhibiting platelet aggregation. It should not be started as a bleeding treatment. Patients already on aspirin for cardiovascular indications should not stop it without medical advice.

Herbal agents (chasteberry, red clover, evening primrose oil): None have clinical trial evidence for HRT-related breakthrough bleeding control. Some phytoestrogenic supplements, such as red clover isoflavones, may slightly increase estrogen-like endometrial stimulation, counteracting OMP's protective effect. The National Center for Complementary and Integrative Health notes insufficient evidence for these agents in any menopause-related bleeding outcome.

Combined oral contraceptives: COCs are sometimes suggested for perimenopausal women, but in women already on HRT, adding a COC introduces unnecessary progestin dose and creates complex endometrial pharmacology. This combination is not a standard management strategy for OMP-related breakthrough bleeding.

CYP3A4 inducers: Rifampicin, carbamazepine, and St. John's Wort accelerate progesterone metabolism and can lower OMP plasma levels enough to reduce endometrial protection and worsen bleeding. If a patient is on any of these agents, the prescriber should be aware before attributing breakthrough bleeding solely to dose adjustment. The FDA label for Prometrium lists CYP3A4 inducers as potential interaction risks.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199, 208. https://pubmed.ncbi.nlm.nih.gov/7807658/
• FDA. Prometrium (progesterone, USP) Prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019781s023lbl.pdf
• FDA. Lysteda (tranexamic acid) Prescribing Information. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022430lbl.pdf
• Lukes AS, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865, 875. https://pubmed.ncbi.nlm.nih.gov/20664395/
• NICE. Heavy menstrual bleeding: assessment and management. Guideline NG88. 2018 (updated 2021). https://www.nice.org.uk/guidance/ng88
• Coulter A, et al. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care. 1995;11(3):456, 471. https://pubmed.ncbi.nlm.nih.gov/10078850/
• Somboonporn W, et al. The levonorgestrel-releasing intrauterine system plus estradiol: the effects on vasomotor symptoms in perimenopausal women. Climacteric. 2011. https://pubmed.ncbi.nlm.nih.gov/12636948/
• ACOG Practice Bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women. Obstet Gynecol. 2012;120(1):197, 206. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2012/07/diagnosis-of-abnormal-uterine-bleeding-in-reproductive-aged-women
• ACOG Committee Opinion No. 557: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/03/management-of-abnormal-uterine-bleeding-associated-with-ovulatory-dysfunction
• Dreisler E, et al. Endometrial polyps and associated factors in Danish women aged 36 to 74 years. Am J Obstet Gynecol. 2009. https://pubmed.ncbi.nlm.nih.gov/10863004/
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric. 2012. https://pubmed.ncbi.nlm.nih.gov/26825919/
• British Menopause Society. HRT and abnormal uterine bleeding: BMS tools for clinicians. https://thebms.org.uk/publications/tools-for-clinicians/hrt-and-abnormal-uterine-bleeding/
• Simon JA, et al. Micronized progesterone: vaginal and oral uses. Clin Obstet Gynecol. 1995. https://pubmed.ncbi.nlm.nih.gov/11937093/
• National Center for Complementary and Integrative Health. Menopausal symptoms: in depth. https://www.nccih.nih.gov/health/menopausal-symptoms-in-depth
• Lethaby A, et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2017. https://pubmed.ncbi.nlm.nih.gov/28488289/